Not Yet RecruitingNot Applicable

CKM Syndrome Prevalence and Its Association With SCORE-2 and BRI

Turkey (Türkiye)400 participantsStarted 2025-06-01

Plain-language summary

This cross-sectional study aims to determine the prevalence of Cardiovascular-Kidney-Metabolic (CKM) syndrome in a community-based adult population in Gaziantep, Türkiye. In addition to estimating the prevalence across CKM stages, the study investigates the associations between CKM syndrome and two key risk indicators: the SCORE-2 cardiovascular risk score and Body Roundness Index (BRI). Findings from this study will provide valuable insights into early cardiometabolic risk profiling and support the development of regionally tailored prevention strategies.

Who can participate

Age range30 Years – 79 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria Age between 30 and 79 years Residence in Gaziantep, Türkiye Availability of the following laboratory tests performed within the past 1 month: Fasting glucose HbA1c Lipid profile (total cholesterol, LDL, HDL, triglycerides) Creatinine Estimated glomerular filtration rate (eGFR) Ability to provide informed consent Exclusion Criteria Presence of severe physical or mental disability Hospitalization due to acute illness within the past 3 months Pregnancy

What they're measuring

Prevalence of CKM Syndrome stages (0-4)

Timeframe: At the time of enrollment (single visit)

Trial details

NCT IDNCT06944236

SponsorUniversity of Gaziantep

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-31

Contact for this trial

Yıldız Büyükdereli Atadağ, Asst Prof

+903423601200 yildizatadag@gantep.edu.tr

View on ClinicalTrials.gov More Metabolic Syndrome trials